Roger D.  Tung net worth and biography

Roger Tung Biography and Net Worth

Roger D. Tung, Ph.D. is our scientific founder and has served as our President and Chief Executive Officer and as a member of our board of directors since April 2006. Before Concert, Dr. Tung was a founding scientist at Vertex, a pharmaceutical company, where he was employed from 1989 to 2005, most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry. During his career, Dr. Tung has overseen the discovery of five drugs approved for the treatment of HIV, hepatitis C, and cystic fibrosis and was an inventor of several of them. He also serves as a member of the University of Wisconsin-Madison School of Pharmacy’s Board of Visitors, faculty mentor in the MIT IMPACT program, and strategic advisor to Longwood Founder’s Fund. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison.

What is Roger D. Tung's net worth?

The estimated net worth of Roger D. Tung is at least $8.13 million as of January 6th, 2023. Dr. Tung owns 971,018 shares of Concert Pharmaceuticals stock worth more than $8,127,421 as of April 23rd. This net worth evaluation does not reflect any other assets that Dr. Tung may own. Learn More about Roger D. Tung's net worth.

How do I contact Roger D. Tung?

The corporate mailing address for Dr. Tung and other Concert Pharmaceuticals executives is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. Concert Pharmaceuticals can also be reached via phone at (781) 860-0045 and via email at [email protected]. Learn More on Roger D. Tung's contact information.

Has Roger D. Tung been buying or selling shares of Concert Pharmaceuticals?

Roger D. Tung has not been actively trading shares of Concert Pharmaceuticals during the past quarter. Most recently, Roger D. Tung sold 9,240 shares of the business's stock in a transaction on Friday, January 6th. The shares were sold at an average price of $7.24, for a transaction totalling $66,897.60. Following the completion of the sale, the chief executive officer now directly owns 971,018 shares of the company's stock, valued at $7,030,170.32. Learn More on Roger D. Tung's trading history.

Who are Concert Pharmaceuticals' active insiders?

Concert Pharmaceuticals' insider roster includes Marc Becker (CFO), James Cassella (Insider), Jeffrey Munsie (Insider), Nancy Stuart (COO), and Roger Tung (CEO). Learn More on Concert Pharmaceuticals' active insiders.

Roger D. Tung Insider Trading History at Concert Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/6/2023Sell9,240$7.24$66,897.60971,018View SEC Filing Icon  
2/15/2022Sell13,480$3.09$41,653.20View SEC Filing Icon  
1/6/2022Sell9,240$3.09$28,551.60View SEC Filing Icon  
12/13/2021Sell6,700$3.62$24,254.00View SEC Filing Icon  
2/17/2021Sell13,480$7.20$97,056.00808,578View SEC Filing Icon  
5/11/2016Buy19,610$10.55$206,885.50538,965View SEC Filing Icon  
See Full Table

Roger D. Tung Buying and Selling Activity at Concert Pharmaceuticals

This chart shows Roger D Tung's buying and selling at Concert Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Concert Pharmaceuticals Company Overview

Concert Pharmaceuticals logo
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $8.37
Low: $8.37
High: $8.37

50 Day Range

MA: $8.37
Low: $8.33
High: $8.40

2 Week Range

Now: $8.37
Low: $2.66
High: $8.55

Volume

N/A

Average Volume

2,970,800 shs

Market Capitalization

$401.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52